On 2018-july-13, information was received from a healthcare professional (hcp) via a manufacturer representative (rep) regarding a patient receiving bupivacaine (2 mg/ml, 0.863 mg/day) and morphine (3 mg/ml, 1.3 mg/day) via an implantable pump for non-malignant pain and cervical/neck.On (b)(6) 2018, initial interrogation of the patient's pump indicated a motor stall occurred.The hcp denied any electromagnetic interference (emi), magnetic interaction, or mris.The rep indicated that the patient heard their pump alarming and was seen in the emergency room (er) with withdrawal symptoms; nausea, insomnia, flu-like symptoms and increased pain.Pump status and/or event log report showed motor stall occurred, motor stall (active), motor stall and recovery, and stopped pump period may exceed tube set.No further information was provided at this point.
|